Trial reportSurgery today2016
The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis.
Trial report in Surgery today, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06312683 (Rifaximin for the Secondary Prevention of Recurrent Pouchitis), which is not on this map. Cited by 71 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Who cites it
71 citing papers in PubMed, 7 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2025Pooled it
- AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.Gastroenterology · 2024Guideline
- A Systematic Review and Meta-analysis of Randomized Clinical Trials on the Prevention and Treatment of Pouchitis after Ileoanal Pouch Anastomosis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Pooled it
- Disease Activity Indices for Pouchitis: A Systematic Review.Inflammatory bowel diseases · 2022Pooled it
- AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.Gastroenterology · 2020Guideline
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.The Cochrane database of systematic reviews · 2019Pooled it
- Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis.The Korean journal of internal medicine · 2022Trial
- Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis.Digestive diseases and sciences · 2018Trial
- The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.Scientific reports · 2018Trial
- Clinical analysis of 16 patients withNew microbes and new infections · 2026Article
- Review
- Anatomical, physiological, and luminal adaptations occurring in an ileoanal pouch: opportunities for improving outcomes.Inflammatory bowel diseases · 2026Review
- Current Understanding of Probiotic Strains and Immune Function: From Gut Microbiota to Systemic Immunity.International journal of molecular sciences · 2026Review
- Comparative population genomics reveal the genetic features associated with the plant host adaptation of Clostridium butyricum.BMC genomics · 2026Article
- From One-Size-Fits-All to Precision Medicine: The Promise of Personalized Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Research trends on autoimmune liver diseases and gut microbiota (1989-2025): a bibliometric and visualization analysis based on the web of science core collection database.Frontiers in immunology · 2026Article
- Genomic insights and metabolic profiling of gut commensal Luoshenia tenuis at strain level.NPJ biofilms and microbiomes · 2025Article
- The Role of Gut Microbiota in Gastrointestinal Immune Homeostasis and Inflammation: Implications for Inflammatory Bowel Disease.Biomedicines · 2025Review
- Preventive effect of Clostridium butyricum MIYAIRI against pouchitis in children with ulcerative colitis.Surgery today · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUlcerative colitis (UC) is a chronic, relapsing, and refractory disorder of the intestine. Total proctocolectomy with ileal pouch anal anastomosis (IPAA) is the preferred and standard surgical procedure for patients' refractory to medical therapy. Pouchitis is one of the most common long-term complications after IPAA. In the present study, the safety and efficacy of Clostridium butyricum MIYAIRI (CBM) as a probiotic were examined.
methodsA randomized and placebo-controlled study was performed. Seventeen patients were recruited from 2007 to 2013. Nine tablets of MIYA-BM(®) or placebo were orally administered once daily. The cumulative pouchitis-free survival, pouch condition (using the modified pouch disease activity index), and blood parameters were evaluated. A fecal sample analysis was also performed.
resultsSubjects were randomly allocated to receive MIYA-BM or placebo (9 and 8 subjects, respectively). One subject in the MIYA-BM group and four subjects in the placebo group developed pouchitis. No side effects occurred in either group. Characteristic intestinal flora was observed in each group.
conclusionsOur results suggest that probiotic therapy with CBM achieved favorable results with minimal side effects and might be a useful complementary therapy for the prevention of pouchitis in patients with UC who have undergone IPAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.